VivoSeq
Other

Solid Organ Transplant

0

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Solid Organ Transplant is an early-stage landscape with 0 programs across 3 companies. The most active players are Novartis, Astellas, Direct Biologics, LLC.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

78/100

Attrition Rate

13/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

0 programs

PreclinicalAstellas logo

Astellas

0 programs

PreclinicalD

Direct Biologics, LLC

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed7 · 47%
No longer available2 · 13%
Terminated1 · 7%
Active, not recruiting1 · 7%
Unknown status1 · 7%
Recruiting1 · 7%
Other2 · 13%

Clinical Trials

Trial Activity

15 trials

Utilising Genotype Informed Bayesian Dosing of Tacrolimus in Children Post Solid Organ Transplantation.
Recruiting·MMurdoch Childrens Research Institute·Phase 4·NCT06529536·45 enrolled
Viral Specific T-cells for Treatment of Viral Infections After Solid Organ Transplant
Active, not recruiting·—·Phase 2·NCT04331275·42 enrolled
Feeding the Flame, One Day at a Time: Design and Acceptability of a Serious Game to Support Medication Adherence and Education for Pediatric Solid Organ Transplant Patients
Not yet recruiting·SStanford University·Preclinical·NCT07609303·15 enrolled
Safety and Immunogenicity of 7-Valent Pneumococcal Conjugate Vaccine in Children Receiving Solid Organ Transplants
Completed·TThe Hospital for Sick Children·Phase 3·NCT00213265·81 enrolled
Standard-dose Versus High-dose Flu Vaccine in Solid Organ Transplant.
Completed·IInova Health Care Services·Phase 4·NCT01808456·62 enrolled
A Study to Determine Pharmacokinetics of Children Receiving Modigraf (Tacrolimus Granules) Following Solid Organ Transplantation
Completed·Astellas logoAstellas·Phase 4·NCT01371331·52 enrolled
Standard Dose Versus High-Dose Inactivated Flu Vaccine in Pediatric Solid Organ Transplant Patients
Completed·VVanderbilt University·Phase 1·NCT01525004·38 enrolled
Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients
Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 4·NCT03360682·19 enrolled
The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation
Completed·TThe Hospital for Sick Children·Phase 3·NCT00213304·21 enrolled
Safety and Efficacy of ProQuad® in Children 6-24 Month Being Evaluated for Solid Organ Transplant
Completed·MMedical University of South Carolina·Phase 1·NCT02687763·5 enrolled
Solid Organ Transplant SHINGRIX
Terminated·EEmory University·N/A·NCT03993717·2 enrolled
FMT for MDRO Colonization in Solid Organ Transplant
Withdrawn·UUniversity of Miami·Phase 1·NCT02816437
A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation
No longer available·Novartis logoNovartis·N/A·NCT00149981
Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation
Unknown status·UUniversity of Sydney·Phase 1·NCT02779439·25 enrolled
Expanded Access for Use of ExoFlo in Abdominal Solid Organ Transplant Patients
No longer available·DDirect Biologics, LLC·N/A·NCT05215288

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)